

Opiant Pharmaceuticals Inc (OPNT) - Financial and Strategic SWOT Analysis Review

<https://marketpublishers.com/r/O437483ABBBEN.html>

Date: September 2021

Pages: 53

Price: US\$ 125.00 (Single User License)

ID: O437483ABBBEN

Abstracts

Opiant Pharmaceuticals Inc (OPNT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

Business description – A detailed description of the company's operations and business divisions.

Corporate strategy – Analyst's summarization of the company's business strategy.

SWOT Analysis – A detailed analysis of the company's strengths, weakness, opportunities and threats.

Company history – Progression of key events associated with the company.

Major products and services – A list of major products, services and brands of the company.

Key competitors – A list of key competitors to the company.

Key employees – A list of the key executives of the company.

Executive biographies – A brief summary of the executives' employment history.

Key operational heads – A list of personnel heading key departments/functions.

Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.

Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Opiant Pharmaceuticals Inc (Opiant), formerly, Lightlake Therapeutics Inc is a specialty pharmaceutical company that develops pharmacological treatments for substance use, addiction and eating disorders. It focuses on developing treatments to reverse opioid overdoses, alcohol use disorder, acute cannabinoid overdose, and opioid use disorder. The company develops products based on its patented novel opioid antagonist nasal delivery technology. Opiant developed NARCAN (naloxone hydrochloride) nasal spray, a treatment to reverse opioid overdose. The product is approved for marketing in the US by its partner, Adapt Pharma. Opiant is headquartered in Santa Monica, California, the US.

Opiant Pharmaceuticals Inc Key Recent Developments

Aug 25,2021: Opiant Pharmaceuticals to Participate in September Investor Conferences

Jul 20,2021: Opiant Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jul 12,2021: Opiant Pharmaceuticals Announces Appointment of Matthew Ruth as Chief Commercial Officer

May 18,2021: Opiant Pharmaceuticals to Hold Virtual 2021 Annual Shareholder Meeting

on Tuesday, June 15, 2021 at 9:00am PDT

May 11,2021: Opiant Pharmaceuticals Announces First Quarter 2021 Financial Results and Corporate Update

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Contents

SECTION 1 - ABOUT THE COMPANY

Opiant Pharmaceuticals Inc - Key Facts
Opiant Pharmaceuticals Inc - Key Employees
Opiant Pharmaceuticals Inc - Key Employee Biographies
Opiant Pharmaceuticals Inc - Major Products and Services
Opiant Pharmaceuticals Inc - History
Opiant Pharmaceuticals Inc - Company Statement
Opiant Pharmaceuticals Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Company Overview
Opiant Pharmaceuticals Inc - Business Description
Business Segment: Grant and Contract revenue
Performance
Business Segment: Royalty and Licensing revenue
Performance
Business Segment: Treatment Investment revenue
Performance
Opiant Pharmaceuticals Inc - Corporate Strategy
Opiant Pharmaceuticals Inc - SWOT Analysis
SWOT Analysis - Overview
Opiant Pharmaceuticals Inc - Strengths
Opiant Pharmaceuticals Inc - Weaknesses
Opiant Pharmaceuticals Inc - Opportunities
Opiant Pharmaceuticals Inc - Threats
Opiant Pharmaceuticals Inc - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance

Financial Ratios - Interim Ratios

Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Opiant Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021

Opiant Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021

Opiant Pharmaceuticals Inc, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Aug 25, 2021: Opiant Pharmaceuticals to Participate in September Investor Conferences

Jul 12, 2021: Opiant Pharmaceuticals Announces Appointment of Matthew Ruth as Chief Commercial Officer

May 18, 2021: Opiant Pharmaceuticals to Hold Virtual 2021 Annual Shareholder Meeting on Tuesday, June 15, 2021 at 9:00am PDT

May 11, 2021: Opiant Pharmaceuticals Announces First Quarter 2021 Financial Results and Corporate Update

Mar 22, 2021: Opiant Pharmaceuticals Strengthens Board of Directors With Appointment of Seasoned Clinical Development Executive Lorianne Masuoka, M.D.

Feb 22, 2021: Opiant Pharmaceuticals to Report Fourth Quarter 2020 Financial Results and Host Conference Call and Webcast on March 4, 2021

Dec 07, 2020: Opiant Pharmaceuticals announces appointment of biopharmaceutical leader Craig A. Collard as Chairman to its Board of Directors

Nov 12, 2020: Opiant Pharmaceuticals announces third quarter 2020 financial results and corporate update

Oct 27, 2020: Opiant Pharmaceuticals to Report Third Quarter 2020 Financial Results and Host Conference Call and Webcast on November 12, 2020

Aug 06, 2020: Opiant Pharmaceuticals announces second quarter 2020 financial results and corporate update

SECTION 6 – APPENDIX

Methodology

Ratio Definitions

About GlobalData

[Contact Us](#)
[Disclaimer](#)

List Of Tables

LIST OF TABLES

Opiant Pharmaceuticals Inc, Key Facts
Opiant Pharmaceuticals Inc, Key Employees
Opiant Pharmaceuticals Inc, Key Employee Biographies
Opiant Pharmaceuticals Inc, Major Products and Services
Opiant Pharmaceuticals Inc, History
Opiant Pharmaceuticals Inc, Subsidiaries
Opiant Pharmaceuticals Inc, Key Competitors
Opiant Pharmaceuticals Inc, Ratios based on current share price
Opiant Pharmaceuticals Inc, Annual Ratios
Opiant Pharmaceuticals Inc, Annual Ratios (Cont...1)
Opiant Pharmaceuticals Inc, Annual Ratios (Cont...2)
Opiant Pharmaceuticals Inc, Interim Ratios
Opiant Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Opiant Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Opiant Pharmaceuticals Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List Of Figures

LIST OF FIGURES

Opiant Pharmaceuticals Inc, Performance Chart (2016 - 2020)

Opiant Pharmaceuticals Inc, Ratio Charts

Opiant Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021

Opiant Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021

I would like to order

Product name: Opiant Pharmaceuticals Inc (OPNT) - Financial and Strategic SWOT Analysis Review

Product link: <https://marketpublishers.com/r/O437483ABBBEN.html>

Price: US\$ 125.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/O437483ABBBEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970